Format

Send to

Choose Destination
Mov Disord Clin Pract. 2018 Jan-Feb;5(1):47-53. doi: 10.1002/mdc3.12553. Epub 2017 Sep 22.

Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.

Author information

1
Department of Neurology, University of Colorado Anschutz Medical Campus, Aurora, CO USA.
2
Department of Neurology, Aurora St. Luke's Medical Center, Milwaukee, WI.
3
Neurology Section, Denver VA Medical Center, Denver, CO USA.

Abstract

Background:

The Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UDPRS) is a commonly used tool to measure Parkinson disease (PD) progression. Longitudinal changes in MDS-UPDRS scores in de novo PD have not been established.

Objective:

Determine progression rates of MDS-UPDRS scores in de novo PD.

Methods:

362 participants from the Parkinson's Progression Markers Initiative, a multicenter longitudinal cohort study of de novo PD, were included. Longitudinal progression of MDS-UPDRS total and subscale scores were modeled using mixed model regression.

Results:

MDS-UPDRS scores increased in a linear fashion over five years in de novo PD. MDS-UPDRS total score increased an estimated 4.0 points/year, Part I 0.25 points/year, Part II 1.0 points/year, and Part III 2.4 points/year.

Conclusions:

The expected average progression of MDS-UPDRS scores in de novo PD from this study can assist in clinical monitoring and provide comparative data for detection of disease modification in treatment trials.

KEYWORDS:

MDS-UPDRS; Parkinson disease; biomarkers; disease progression

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center